Menu
Recruiting NCT04099134

PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma

— Observational Pancreas Adenocarcinoma Pancreas Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Pancreas Adenocarcinoma, Pancreas Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

PaCaReg: A Multicenter Registry Trial for the Assessement of Clinical, Epidemiological and Biological Profiles in Patients With Pancreatic Ductal Adenocarcinoma

Overview

PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma

Primary outcome measures

  • General assessment of applied therapy modalities in pancreatic cancer [Time frame: First diagnose to death or end of surveillance (5 years after curative resection)]
  • Quality of life in pancreatic cancer patients [Time frame: First diagnose to death or end of surveillance (5 years after curative resection)]
Secondary outcome measures (3)
  • General epidemiologic assessment [Time frame: First diagnose to death or end of surveillance (5 years after curative resection)]
  • Assessment of tumor surveillance in pancreatic cancer patients [Time frame: First diagnose to death or end of surveillance (5 years after curative resection)]
  • Evaluation of predictive and prognostic markers [Time frame: First diagnose to death or end of surveillance (5 years after curative resection)]

Eligibility criteria

Inclusion criteria

  • Treatment naive histologically or cytologically proven pancreatic ductal adenocarcinoma (PDAC) or highly suspicious diagnosis (only pre-curative-intended resection)
  • Age =>18 years
  • written informed consent

Exclusion criteria

  • papillary cancer
  • neuroendocrine pancreatic tumors

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

Germany · 1 center
  • Universitätsklinikum Ulm — Ulm

Identifiers

NCT: NCT04099134 · PaCaReg

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗